Cancer-Patient Population Projections (Cancer-PPP)

Colorectal cancer projections for the Australian population are now available on the Colorectal Cancer Projections Dashboard. By accessing or utilising the Projections within the Dashboard, you are agreeing to be bound by our Terms and Conditions for Projections, which can be located on the Dashboard, and are acknowledging that you have read and understood the listed disclaimers.

As part of the Cancer PPP project, updated cancer incidence trends and evidence-based treatment protocols have been incorporated into the existing Policy1-Bowel model. This will allow detailed five-year predictions to be made about the number of patients requiring treatment in Australia, including those on new targeted therapies.

The breast cancer team is enhancing the Policy1-Breast model to incorporate breast cancer subtypes and risk-based screening protocols. The model can then be used to provide informative predictions about incidence, mortality, and treatment costs by breast cancer subtype.

The lung cancer team is working to adapt Policy1-Lung to the lung cancer population, using detailed data on smoking trends. The model will then be used to create five-year predictions on the incidence, mortality and costs of lung cancer.

The melanoma team is including stage-specific treatment pathways, including costs and utilisation patterns of next generation targeted and immunotherapies to Policy1-Melanoma. The model will then be used project five-year outcomes in melanoma by stage of disease at diagnosis and treatment costs.

The multiple myeloma team is working to investigate the disease burden, risk factors, and treatment interventions currently available for multiple myeloma to inform a future Policy1-Multiple Myeloma model.

Evidence from systematic reviews, statistical projections and epidemiological analysis will be used by the pan-tumour biomarkers team to estimate the incidence and prevalence of mismatch repair deficiency, microsatellite instability and high tumour mutation burden in cancer patients.

This research is funded through the Medical Research Future Fund (MRFF) – Preventive and Public Health Research Initiative – 2019 Targeted Health System and Community Organization Research Grant Opportunity (MRF1200535).

We would like to acknowledge and thank the contributions of the Daffodil Centre Research Team listed below, as well as the additional Chief Investigators Dr Phil Haywood and Prof Kwun Fong, and Associate Investigators Prof Ian Olver, Mr Jeff Cuff, Prof John Zalcberg, and Prof Robyn Ward.